Visual association pathology in preclinical Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 6, 2006, Pages 621-630

  McKee, Ann C ^a,c   Au, Rhoda ^a   Cabral, Howard J ^b   Kowall, Neil W ^a   Seshadri, Sudha ^a   Kubilus, Caroline A ^a   Drake, Jon ^a   Wolf, Philip A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Brodmann area 19; Preclinical Alzheimer disease; Visual association cortex

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPIL THREAD; PRIORITY JOURNAL; TEMPORAL LOBE; VASCULAR AMYLOIDOSIS; VISUAL IMPAIRMENT; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SENILE PLAQUE; STATISTICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; COGNITION DISORDERS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; NEUROPIL THREADS; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; SENILE PLAQUES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 33746772217     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-200606000-00010     Document Type: Article

References (60)

1. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999;45:358-68
2. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808-13
3. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101-18
4. Schmitt FA, Davis DG, Wekstein DR, et al. 'Preclinical' AD revisited: Neuropathology of cognitively normal older adults. Neurology 2000;55:370-76
5. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in 'normal' aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168-74
6. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
7. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365-71
8. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001;56:361-67
9. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-97
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59
11. Klunk WE Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B. Ann Neurol 2004;55:306-19
12. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17
13. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
14. Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F] fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590-98
15. Bonte FJ, Ross ED, Chehabi HH, Devous MD Sr. SPECT study of regional cerebral blood flow in Alzheimer disease. J Comput Assist Tomogr 1986;10:579-83
16. Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: Relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996;60:644-49
17. Masterman DL, Mendez MF, Fairbanks LA, Cummings JL. Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. J Geriatr Psychiatry Neurol 1997;10:15-21
18. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12:851-55
19. Silverman DH, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: Comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003;80:350-55
20. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-13
21. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-77
22. Buckner RL, Head D, Parker J, et al. A unified approach for the morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: Reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724-38
23. Tetewsky SJ, Duffy CJ. Visual loss and getting lost in Alzheimer's disease. Neurology 1999;52:958-65
24. Mapstone M, Steffenella TM, Duffy CJ. A visuospatial variant of mild cognitive impairment: Getting lost between aging and AD. Neurology 2003;60:802-8
25. Monacelli AM, Cushman LA, Kavcic V, Duffy CJ. Spatial disorientation in Alzheimer's disease: The remembrance of things passed. Neurology 2003;61:1491-97
26. Kawas CH, Corrada MM, Brookmeyer R, et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 2003;60:1089-93
27. Giambra LM, Arenberg D, Kawas C, et al. Adult life span changes in immediate visual memory and verbal intelligence. Psychol Aging 1995;10:123-39
28. Zonderman AB, Giambra LM, Arenberg D, et al. Changes in immediate visual memory predict cognitive impairment. Arch Clin Neuropsychol 1995;10:111-23
29. Fabrigoule C, Rouch I, Taberly A, et al. Cognitive process in preclinical phase of dementia. Brain 1998;121:135-41
30. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
31. Davis PB, White H, Price JL, et al. Retrospective postmortem dementia assessment. Validation of a new clinical interview to assist neuropathologic study. Arch Neurol 1991;48:613-17
32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14
33. Runeson BS, Rich CL. Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann Clin Psychiatry 1994;6:181-83
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
35. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study. Neurology 1993;43:515-19
36. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 1997;49:1498-1504
37. Von Economo C. The Cytoarchitectonics of the Human Cerebral Cortex. London:Humphrey Milford Oxford University Press,1920
38. Brodmann K. Vergleichende Lokalisationslehre der Grosshimrinde in ihren Prinzipien dargestellt auf Grund des Zellenbaues. Leipzig: Barth, 1909
39. McKee AC, Kosik S, Kowall NW. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 1991;30:156-65
40. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Ann Neurol 1991;30:637-49
41. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53
42. Mishkin M, Ungerleider LG, Macko KA. Object vision and spatial vision: Two cortical pathways. Trends Neurosci 1983;6:414-17
43. Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003;23:994-1005
44. Teipel SJ, Alexander GE, Schapiro MB, Moller HJ, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain 2004;127:811-24
45. Grady CL, Maisog JM, Horwitz B. Age-related changes in cortical blood flow activation during visual processing of faces and location. J Neurosci 1994;14:1450-62
46. Linn RT, Wolf PA, Bachman DL, et al. The preclinical phase of probable Alzheimer's disease. A 13-year prospective study of the Framingham Cohort. Arch Neurol 1995;52:485-90
47. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993;33:403-8
48. Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol 1990;301:55-64
49. Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: A quantitative study of visual and auditory cortices. J Neurosci 1987;7:1799-1808
50. Mendez MF, Mendez MA, Martin R, et al. Complex visual disturbances in Alzheimer's disease. Neurology 1990;40:439-43
51. Mendez MF, Tomsak RL, Remler B. Disorders of the visual system in Alzheimer's disease. J Clin Neuroophthalmol 1990;10:62-9
52. Kumar-Singh S, Pirici D, McGowan E, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005;167:527-43
53. Kumar-Singh S, Cras P, Wang R, et al. Dense-core plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol 2002;161:507-20
54. Suter OC, Sunthorn T, Kraftsik R, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002;33:1986-92
55. Romanul F, Abramowicz A. Changes in brain and pial vessels in arterial broder zones. Arch Neurol 1964;11:40-65
56. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003;6:605-10
57. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33
58. Stepanyants A, Hof PR, Chklovskii DB. Geometry and structural plasticity of synaptic connectivity. Neuron 2002;34:275-88
59. Morrison JH, Lewis DA, Campbell MJ, et al. A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease. Brain Res 1987;416:331-36
60. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-16